Pacira BioSciences Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pacira Pharmaceuticals (PCRX) PT Lowered to $30 at Jefferies
August 1, 2024 3:59 PM EDTJefferies analyst Glen Santangelo lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $30.00 (from $36.00) while maintaining a Buy rating.
The analyst comments "Updating model to reflect 2Q results. Overall, we think NT results remain overshadowed by the pending court ruling... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $37 at RBC Capital
July 31, 2024 6:24 AM EDTRBC Capital analyst Daniel Busb lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $37.00 (from $42.00) while maintaining a Outperform rating.
The analyst comments "While PCRX continues to execute on delivering positive Exparel numbers through 1H, focus remains squarely on ongoing patent... More
